Colorectal Cancer

Geneoscopy adds N.Y. state lab permit for wider ColoSense testing

By LabPulse.com staff writers

Noninvasive colorectal cancer screening test developer Geneoscopy has received a laboratory permit from the New York State Department of Health.

October 1, 2024

New laboratory developed tests for colorectal cancer screening get boost from CMS

By Liz Carey

Clinical laboratory test manufacturers aim for estimated 60 million unscreened Americans as CMS meets them with a broad CRC screening test definition and proposed coverage changes in 2025.

July 31, 2024

Geneoscopy files countersuit against Exact Sciences in patent infringement dispute

By LabPulse.com staff writers

Geneoscopy filed a lawsuit on June 28 against Exact Sciences asserting multiple claims for damages in federal court in the District of Delaware, in the latest development in the ongoing patent dispute between the two companies.

July 1, 2024

Guardant's CRC screening test receives advisory committee recommendation

By LabPulse.com staff writers

Guardant's blood-based Shield screening test for colorectal cancer (CRC) has received the recommendation of the U.S. Food and Drug Administration's Medical Devices Advisory Committee, an important milestone on its path to approval.

May 28, 2024

Geneoscopy receives FDA approval for CRC screening test

By LabPulse.com staff writers

Geneoscopy announced that the U.S. Food and Drug Administration (FDA) has approved ColoSense, the firm's noninvasive multitarget stool RNA colorectal cancer (CRC) screening test.

May 7, 2024

Geneoscopy requests review of Exact Sciences patent, dismissal of lawsuit

By LabPulse.com staff writers

In the latest development in the patent infringement dispute between the two companies, Geneoscopy has petitioned the U.S. Patent and Trademark Office for inter partes review, challenging the patent in contention held by Exact Sciences.

January 12, 2024

Universal DX partners with Quest Diagnostics, closes $70M series B financing round

By LabPulse.com staff writers

Liquid biopsy firm Universal DX and Quest Diagnostics have formed a strategic collaboration under which Quest will exclusively offer services for Universal DX’s Signal-C colorectal cancer screening test in the U.S.

November 21, 2023

FDA grants approval to Takeda’s metastatic colorectal cancer therapy

By LabPulse.com staff writers

The U.S. Food and Drug Administration (FDA) has approved a chemotherapy-free oral target therapy for patients who have been previously treated for metastatic colorectal cancer (mCRC).

November 9, 2023

Researchers engineer bacterial biosensor that can detect tumor DNA

By LabPulse.com staff writers

The technique, dubbed Cellular Assay for Targeted CRISPR-discriminated Horizontal gene transfer and known by the acronym CATCH, was designed to identify specific DNA sequences and mutations outside of cells.

August 14, 2023

Exact Sciences raises full-year guidance due to demand for colorectal cancer test

By Nick Paul Taylor

Revenues for Exact Sciences’ screening business, which sells the Cologuard colorectal cancer stool test, increased by 31% to $462.8 million in the second quarter.

August 10, 2023

New Day Diagnostics inks $12M deal to buy Epigenomics’ cancer technology

By Nick Paul Taylor

Epigenomics has agreed to sell “substantially all” of its assets to New Day Diagnostics, a developer of tests for the early detection and monitoring of disease that merged with EDP Biotech earlier this month.

July 31, 2023

Harvard Medical School, RareCyte developing multiplex imaging for clinical pathology

By Elissa Wolfson

Multiplex imaging technology enables the integration of microscopic analysis with the visualization of molecular markers in individual cells.

June 26, 2023

Page 1 of 6

Next Page